Graphical Abstract.pdf (235.65 kB)
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
media
posted on 2024-02-23, 10:28 authored by AdisRapid Journals on behalf of:, F.D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Douglas Arbetter, Seth Seegobin, Alexandre Kiazand, Katie Streicher, Nuria Martinez-Alier, Taylor S. Cohen, Mark T EsserThe above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
